Pituitary dysfunction after aneurysmal subarachnoidal hemorrhage

Bacigaluppi, Susanna; Robba, Chiara; Bragazzi, Nicola Luigi

doi:10.1016/b978-0-12-820683-6.00004-x

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary outcome in this study was the prevalence of PD in the acute and chronic phases. The acute phase corresponded to the occurrence of symptoms associated with PD within the first 6 months after aSAH, while the chronic phase corresponded to the occurrence of symptoms associated with PD after the first 6 months of aSAH onset [ 18 ]. The secondary outcomes were the deficiency of each of the following hormones: ACTH, GH, TSH, Gn, prolactin, cortisol, or testosterone.…”

Section: Methodsmentioning

confidence: 99%

“…PD after aSAH seriously affects patients’ quality of life and social function and it may last for quite a long time [ 17 ]. Thus, more and more studies focused on the prevalence, early identification and prevention of PD after aSAH [ 18 ]. However, studies on the prevalence of PD after aSAH are based on only a few small cohorts, while studies on the acute and chronic phases of PD are scarce [ 19 – 23 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Pituitary dysfunction (PD) is a common complication after aneurysmal subarachnoid hemorrhage (aSAH). The prevalence of PD varies widely at a global level and no recent meta-analysis is available. Therefore, the aim of our systematic review and meta-analysis was to summarize the updated estimates of worldwide prevalence of PD after aSAH. Methods Scopus, Embase, Web of Science, and PubMed databases were used to comprehensively search the appropriate literature and a random-effects meta-analysis on the results of the available studies was performed. The heterogeneity in the prevalence estimates was evaluated by subgroup analysis in terms of types of PD, and acute and chronic phases of aSAH. The onset of PD within 6 months after aSAH was considered as acute, while that after 6 months was considered as chronic. Results Twenty-seven studies with 1848 patients were included in this analysis. The pooled prevalence of PD in the acute phase was 49.6% (95% CI, 32.4-66.8%), and 30.4% (95% CI, 21.4-39.4%) in the chronic phase. Among the hormonal deficiencies, growth hormone dysfunction was the most prevalent in the acute phase, being 36.0% (95% CI, 21.0-51.0%), while hypoadrenalism was the most prevalent in the chronic phase, being 21.0% (95% CI, 12.0-29.0%). Among the six World Health Organization regions, the South-East Asia Region has the highest prevalence of PD in the acute phase (81.0%, 95%CI, 77.0-86.0%, P < 0.001), while the European Region had the highest prevalence of PD in the chronic phase (33.0%, 95%CI, 24.0-43.0%, P < 0.001). Moreover, single pituitary hormonal dysfunction occurred more frequently than the multiple one, regardless of acute or chronic phase. Conclusions Almost half (49.6%) of the included patients with aSAH developed PD complication in the acute phase, while 30.4% of the patients developed them in the chronic phase. Although prevalence varies globally, the high healthcare burden, morbidity and mortality require greater awareness among clinicians.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

Advances in Prognosis and Related Biomarkers of aSAH

王¹

2022

ACM

View full text Add to dashboard Cite

Prevalence of Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis

Song

Cong

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background As a common complication after aneurysmal subarachnoid hemorrhage, the prevalence of pituitary dysfunction ranges widely at the global level and has not been synthesized by meta-analysis for a few years. Updated estimates of the prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage are urgently needed to improve recognition and attention from medical. Methods We comprehensively searched four literature databases including Scopus, Embase, Web of Science and PubMed, and performed a random-effects meta-analysis for the search results. Heterogeneity in the prevalence estimates was analyzed by subgroup analysis in terms of WHO region and type of pituitary dysfunction. Results 27 studies with 1848 subjects were included in this study. The pooled prevalence of pituitary dysfunction in the acute phase was 49.6% (95% CI, 32.4%-66.8%), and decreased in the chronic phase to 30.4% (95% CI, 21.4%-39.4%). Among the hormonal deficiencies, growth hormone dysfunction was the most prevalent in the acute phase with 36.0% (95% CI, 21.0%-51.0%), and in the chronic phase was hypoadrenalism accounting for 21.0% (95% CI, 12.0%-29.0%). While referring to the WHO region, the prevalence of pituitary dysfunction in the acute phase was the highest in SEARO, up to 81.0% (95%CI, 77.0%-86.0%), while the EURO with the highest prevalence of pituitary dysfunction in the chronic phase, was only 33.0% (95%CI, 24.0%-43.0%). Moreover, single pituitary hormone dysfunction occurred more frequently than that of multiple regardless of in the acute or chronic phase. Conclusions In up to 49.6%, patients with aneurysmal subarachnoid hemorrhage may be complicated with pituitary dysfunction, which deserved more attention. Although the prevalence decreased over time, early detection and early treatment were more beneficial for the quality of life of patients. However, the number of existing studies on PD after aSAH is limited. Therefore, more studies based on larger populations and countries are necessary to provide early warning.

show abstract

Pituitary dysfunction after aneurysmal subarachnoidal hemorrhage

Cited by 3 publications

References 38 publications

Prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

Prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

Advances in Prognosis and Related Biomarkers of aSAH

Prevalence of Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About